The information about the cessation of production and supply of the medicinal product Peptoran 300 mg film-coated tablets (ranitidine)
14.08.2013
Pliva (Croatia) d.o.o., the marketing authorisation holder for Peptoran 300 mg film-coated tablets (ranitidine), has informed the Agency for Medicinal Products and Medical Devices about the cessation of production and supply of the medicinal product Peptoran 300 mg film-coated tablets (ranitidine) and withdrawal of the marketing authorisation. The decision about the cessation of production is not due to quality, efficacy or safe use of the medicine. If their shelf-life has not expired, the available batches may remain on the Croatian market no longer than 18 months after the withdrawal of the marketing authorisation.
For the treatment of Croatian patients, there are other medicinal products from the same therapeutic group that are not affected by that shortage.
